Trastuzumab in metastatic breast cancer after complete remission: How long is enough?

Med Oncol. 2015 Aug;32(8):211. doi: 10.1007/s12032-015-0648-1. Epub 2015 Jun 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology*
  • Disease-Free Survival
  • Female
  • Humans
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Trastuzumab / therapeutic use*

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab